Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Nasal-spraying LiveSpo NAVAX: Probiotics of the next generation for respiratory infections

LiveSpo

HANOI, VIETNAM - Media OutReach - 15 August 2022 - On July 20 nd, the Scientific Reports journal (the Nature) officially annouced a break-through research on using LiveSpo NAVAX probiotic spores in nasal spray form to support the treatment of acute respiratory infections in children infected with respiratory syncytial virus (RSV) [1] Respiratory syncytial virus (RSV) is a leading cause of Acute Respiratory Tract Infections (ARTIs) in young children. The World Health Organization estimates that 48,000-74,000 children - younger than five years old die yearly due to RSV infection. Up to now, there is no available vaccine and specific treatment for RSV-infected children. Researchers at Vietnam National Children’s Hospital conducted the first clinical trial in infected children with Respiratory Syncytial Virus (RSV). They demonstrated the safety and beneficial effects of a nasal-spraying liquid suspension of Bacillus spore probiotics (LiveSpo® NAVAX) in the supportive treatment of ARTIs. The research team published results showing that the nasal-spraying LiveSpo NAVAX) reduced the load of RSV and influenza virus by 300-fold and 1000-fold, and was 50- to 70-fold more effective than physiological saline after 2-3 days of treatment. Semi-quantitative real-time PCR results of co-infection bacteria on day three of treatment show that patients in the NAVAX) group (spraying probiotics spores) were negative while patients in the control group (not using probiotic spores) only had a slight decrease in bacterial co-infection concentration. The team also assessed that the nasal-spraying Bacillus spores could rapidly and effectively relieve symptoms of RSV-induced ARTIs while exhibiting a strong effect in reducing viral load and inflammation. Nasal-spraying probiotics may provide the basis for simple, low-cost, and effective symptomatic adjuvant treatment against viral infections. Dr. Nguyen Hoa Anh - Director of Sporebiotics Research Center said: “The interaction mechanism between LiveSpo NAVAX) 's Bacillus spores and the virus and the nasal mucosal immune system is based on nonspecific binding suggesting that LiveSpo Navax may be helpful against viral variants that cause respiratory diseases or other rapidly emerging respiratory viruses such as influenza virus or coronavirus. The research is a breakthrough scientific achievement, contributing to enhancing the image of Vietnam in the field of science in the international arena and making a great contribution to public health care, especially for children. [1] Scientific Report (July 20th, 2022). “Nasal‑spraying Bacillus spores as an efective symptomatic treatment for children with acute respiratory syncytial virus infection” https://www.nature.com/articles/s41598-022-16136-z.pdf About LiveSpo LiveSpo® NAVAX containing more than 5-billion spores of beneficial bacteria Bacillus subtilis and Bacillus clausii, and 0.9% physiological saline up to 5mL.The product supports to help clean ears, nose, throat; and prevent, reduce the risk of ear, nose, throat infections, and increase beneficial bacteria, protect and the nasal mucosa. Company Website https://livespo.com/en/ Contact Details Media Contact huong.md@livespo.com Company Website https://livespo.com/en/

August 15, 2022 11:43 AM Eastern Daylight Time

Image

Elsevier gives free access to content and resources via just-launched Monkeypox Information Center to accelerate fight against viral disease

Elsevier

For the benefit of healthcare professionals, medical researchers, and the public, Elsevier, a leading scientific publisher and global information analytics business specializing in science and health, has today launched a Monkeypox Information Center. The hub will be continually updated and provide free access to relevant research and clinical information on the Monkeypox virus from across Elsevier’s scientific and medical journals and clinical resources for healthcare professionals. This research and health information will be freely available from Elsevier platforms and shared with the World Health Organization (WHO). In addition, the company, will contribute Monkeypox-relevant journal articles to PubMed Central, the archive of biomedical and life sciences research at the U.S. National Institutes of Health’s National Library of Medicine, for as long as the Monkeypox public health emergency is ongoing. Updated frequently, The Monkeypox Information Center will offer access to journal articles and book chapters to ensure researchers, clinicians and the public can readily discover relevant content from the rapidly growing body of literature. It will also provide a machine-readable corpus to enable use of text and data mining technologies to identify patterns and relationships in data, as countries around the world address this global public health crisis. The Monkeypox Information Center is updated continuously with the latest research information on the virus and the disease. In addition, Monkeypox-related journal articles and book chapters are made freely available on ScienceDirect, Elsevier’s global platform of peer-reviewed scholarly literature. Around 400 journal articles were identified initially, and latest research and guidance will be added as they become available. The launch of this information center is part of Elsevier’s commitment to support the research and healthcare communities in their efforts to address public health emergencies and follows the company’s information hubs for Ebola, SARS, Zika and MERS outbreaks, and the current pandemic response continues to be supported by the existing novel coronavirus resource centre. “The Monkeypox Information Center will support healthcare professionals, clinical researchers, and policy makers in understanding Monkeypox, so that best efforts can be made towards its prevention and treatment,” said Kumsal Bayazit, CEO, Elsevier. “To support research and healthcare communities we serve, with the public health emergency, we are providing an information center where the medical community, patients, and their caregivers can readily access the most up-to-date information.” The Monkeypox Information Center is hosted on Elsevier Connect, the company’s public news and information website. It allows free access to content curated in consultation with Elsevier clinicians and other experts. It brings together content from the company’s journals, books, monographs and clinical information solutions as well as resources from other information providers and major health and government organizations. Also available is information typically used by practicing nurses and physicians, plus resources designed specifically for patients and their families. The site also links to other authoritative resources, including the WHO and the U.S. Centers for Disease Control and Prevention. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals’ advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ digitized journals, including The Lancet and Cell; our 43,000+ eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com. Contact Details Elsevier Andrew Davis +44 7393 242466 andrew.davis@elsevier.com Elsevier Communications, US Dan DiPietro-James +1 773-251-8744 dan.james@elsevier.com Company Website https://www.elsevier.com/

August 15, 2022 04:00 AM Eastern Daylight Time

This Electric Toothbrush Has 6 Cleaning Modes For Reportedly Brighter Smiles

Bruush Oral Care Inc.

https://profiles.smallcapsdaily.com/bruush/ Toothbrushes have come a long way since Babylonians and Egyptians started brushing their teeth with frayed twigs around 3000 BCE. The first more modern toothbrush with a handle carved from cattle bone and a brush made from swine bristles was produced in England around 1780. Natural bristles were used until DuPont de Nemours Inc. (NYSE: DD) invented nylon, which started the development of the truly modern toothbrush in 1938 and the first electric toothbrush in 1939. Although electric toothbrushes date back more than 80 years, they have seemingly not achieved widespread adoption. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. Electric toothbrushes clean teeth, gums and tongue by using rotation or side-by-side movement of the head. Electric toothbrushes are an effective way to remove plaque and reduce gingivitis, and studies show they are more thorough at cleaning teeth than traditional manual toothbrushes. But the moderate adoption rate of the devices arguably demonstrates that consumers need to be educated and provided compelling value propositions to buy them. Cost is a major constraint to the market, and people don’t see them as an attractive addition to their bathroom countertops. Better Brushing? Enter Brüush (NASDAQ: BRSH). While most electric toothbrushes provide 500 strokes per minute, Brüush says its model provides up to 31,000 strokes per minute, attacking plaque 100 times more vigorously than a manual toothbrush. Brüush has six cleaning modes for every type of brusher. The Brüush lithium-ion battery is built to last four weeks on a single charge, and the compact magnetic case makes traveling with the device convenient. The Brüush toothbrush, which comes in five colors with three brush heads and a USB power adapter and charger, retails for $79. And if you sign up for a subscription, Brüush will send you three new brush heads every six months for $18 — that’s just $6 per brush head. Replacing brush heads for Koninklijke Philips N.V.’s (NYSE: PHG) Sonicare can cost as much as $43 for a three-pack, and the price of Procter & Gamble Co. (NYSE: PG) Oral-B line of brush heads reaches as high as $40 for a three-pack, depending on the model. Brüush estimates that 70% of its customer base is between ages 18 and 45 years old, a group that’s under-penetrated compared to baby boomers in terms of using an electric toothbrush. This age group also consists of the first digital generation when it comes to shopping, possibly a positive for a company where its website accounts for the majority of sales. Visit Brüush’s website to learn more about the company and its products. About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR Colette Eymontt colette@tradigitalir.com Company Website https://www.bruush.com

August 11, 2022 01:41 PM Eastern Daylight Time

This Electric Toothbrush Has 6 Cleaning Modes For Reportedly Brighter Smiles

Benzinga

Toothbrushes have come a long way since Babylonians and Egyptians started brushing their teeth with frayed twigs around 3000 BCE. The first more modern toothbrush with a handle carved from cattle bone and a brush made from swine bristles was produced in England around 1780. Natural bristles were used until DuPont de Nemours Inc. (NYSE: DD) invented nylon, which started the development of the truly modern toothbrush in 1938 and the first electric toothbrush in 1939. Although electric toothbrushes date back more than 80 years, they have seemingly not achieved widespread adoption. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. Electric toothbrushes clean teeth, gums and tongue by using rotation or side-by-side movement of the head. Electric toothbrushes are an effective way to remove plaque and reduce gingivitis, and studies show they are more thorough at cleaning teeth than traditional manual toothbrushes. But the moderate adoption rate of the devices arguably demonstrates that consumers need to be educated and provided compelling value propositions to buy them. Cost is a major constraint to the market, and people don’t see them as an attractive addition to their bathroom countertops. Better Brushing? Enter Brüush (NASDAQ: BRSH). While most electric toothbrushes provide 500 strokes per minute, Brüush says its model provides up to 31,000 strokes per minute, attacking plaque 100 times more vigorously than a manual toothbrush. Brüush has six cleaning modes for every type of brusher. The Brüush lithium-ion battery is built to last four weeks on a single charge, and the compact magnetic case makes traveling with the device convenient. The Brüush toothbrush, which comes in five colors with three brush heads and a USB power adapter and charger, retails for $79. And if you sign up for a subscription, Brüush will send you three new brush heads every six months for $18 — that’s just $6 per brush head. Replacing brush heads for Koninklijke Philips N.V.’ s (NYSE: PHG) Sonicare can cost as much as $43 for a three-pack, and the price of Procter & Gamble Co. (NYSE: PG) Oral-B line of brush heads reaches as high as $40 for a three-pack, depending on the model. Brüush estimates that 70% of its customer base is between ages 18 and 45 years old, a group that’s under-penetrated compared to baby boomers in terms of using an electric toothbrush. This age group also consists of the first digital generation when it comes to shopping, possibly a positive for a company where its website accounts for the majority of sales. Visit Brüush’s website to learn more about the company and its products. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 11, 2022 09:52 AM Eastern Daylight Time

Ellie Diagnostics Expands its Laboratory Services to Louisville, Kentucky

Ellie Diagnostics

National flagship laboratory brings innovation to the veterinary industry Ellie Diagnostics, the leading independent diagnostics services provider for veterinarians, today announced the official grand opening of its newest laboratory in Louisville, Kentucky. This modern laboratory provides veterinary clinics across the country with a broad array of highly accurate diagnostic results just hours after patient samples are sent to the lab, and it will employ up to 100 veterinary professionals. Construction on this impressive 33,000 sq./ft. facility began in March 2022, and after an extremely fast development timeline, now enables Ellie Diagnostics to significantly expand its footprint across the United States. This innovative lab, located near the world’s largest UPS air hub in Louisville, will support all veterinarians with the best care, customized services, and flexibility to help grow their practice by identifying and treating diseases earlier than ever before. “Rapid growth in the veterinary industry and increasing demand for high quality, contract-free laboratory services prompted Ellie Diagnostics to open this large state-of-the-art laboratory,” said Founder and Chief Executive Officer Mark DeCourcy. “It is an immense pleasure to expand our operations to the great city of Louisville, and we would like to thank the government officials of Kentucky for their continued support through this process. Our gorgeous new lab is an amazing place to work for veterinary professionals and offers a wonderful environment for individuals looking to help pets on a larger scale.” Ellie Diagnostics ensures next day, early-morning patients’ diagnostic so veterinarians can quickly determine the underlying disease and begin treatment, thereby helping pets live longer, healthier lives. In addition, several tests come with an industry-leading Wellie Report that helps consumers understand their pets’ health and the importance of annual bloodwork for preventative care. About Ellie Diagnostics Ellie Diagnostics is the fastest growing independent veterinary diagnostics company in the United States, providing innovative services to veterinarians nationwide. Ellie provides next-day lab results, complimentary shipping, pathology consultations, data protection, mobile access to orders and results and innovative laboratory reporting. Their comprehensive test menu includes routine lab testing, histopathology, cytology, microbiology, and a wide variety of specialty tests. To learn more, visit www.elliediagnostics.com. Contact Details Ellie Diagnostics Jeff Gwynn, Vice President of Marketing +1 972-619-9969 jgwynn@elliediagnostics.com Company Website https://www.elliediagnostics.com/

August 11, 2022 09:30 AM Eastern Daylight Time

This Company Reports Moving Toward FDA Approval To Provide Pain-Free Diabetes Monitoring

Benzinga

Caused predominantly by genetic predisposition, immune disorders and other factors, such as unhealthy diet and exercise habits, diabetes is one of the most common lifelong chronic diseases in the world. According to the World Health Organization (WHO), there are nearly 450 million cases of diabetes worldwide, and the number in the U.S. could reach 40 million by 2030 and more than 60 million by 2060. Many believe the numbers could be more significant because large numbers of the population might be undiagnosed and at high risk. In recent years, with the rise of global diabetes expected to reach nearly 700 million by 2035, a growing number of patients are suffering from pain and infections caused by the invasive and frequent nature of using mainstream commercial glucose meters. The most common cutaneous complications are wear-related erythema, itching, and induration, but more severe cases, typically related to bacteria infection, continue to grow as well ( source 1 and 2 ). This has led to the need for noninvasive blood glucose monitoring technology, which could relieve numerous issues that many diabetes patients face. Noninvasive blood glucose monitoring refers to the detection of human blood glucose without causing damage to human tissues. Many noninvasive blood glucose detection methods can be divided into the optical, microwave and electrochemical processes. Medical imaging technologies are gaining global relevance in the medical community to assist clinicians in the diagnosis and guiding therapeutic treatment of patients. The big plus is that it's noninvasive and offers high-resolution results. The most common medical imaging technologies are computed tomography, magnetic resonance imaging and ultrasonography. Noninvasive imaging techniques are used in almost every medical field as a diagnostic tool and to monitor pathological progression or the efficacy of treatments. Several imaging tools are available to provide structural and functional information about tissue and organ physiology. New hybrid devices and multimodal imaging offer opportunities for research and use in clinics. Companies like General Electric Co. (NYSE: GE) Healthcare, Lantheus Holdings Inc. (NASDAQ: LNTH), Varex Imaging Corp. (NASDAQ: VREX) and OSI Systems Inc. (NASDAQ: OSIS) have invested heavily in medical imaging products, but most are better known for other medical offerings or other industries altogether. Know Labs Inc. (OTCQB: KNWN), an emerging developer in noninvasive medical diagnostics, focuses on developing its proprietary spectroscopic technologies using the electromagnetic spectrum. The goal is to accurately identify and measure a wide range of organic and inorganic materials, molecules and compositions of matter. Know Labs’ technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It refers to its technology as Bio-RFID™, which can be integrated into various wearable, mobile or bench-top devices. The company’s patented and patent-pending technology makes it possible to effectively identify and monitor analyses that could only previously be performed by invasive, expensive and time-consuming lab-based tests. The first application of its Bio-RFID technology will reportedly be in a product marketed as a noninvasive glucose monitor, giving the user real-time information on blood glucose levels. Know Labs’ leadership says it's confident it will be the first company to bring an FDA-cleared noninvasive glucose monitoring device to market. Know Labs is conducting a 200-person internal clinical trial of Bio-RFID, which will help the company refine its algorithm and demonstrate Bio-RFID’s accuracy in a large population.. Previous internal tests demonstrated Bio-RFID has an accuracy on par or better than currently available solutions, which is an important step towards FDA submission. For more information on Know Labs Inc., visit knowlabs.co. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 10, 2022 02:58 PM Eastern Daylight Time

CleverTap Raises US$105M in Series D Funding Round Led by CDPQ

CleverTap

CleverTap, a leading global B2B SaaS platform for customer engagement and retention today announced it has signed definitive agreements to raise US$105M in a Series D funding round led by CDPQ, a global investment group who committed US$75M, with participation from IIFL AMC’s Tech Fund, along with existing investors Tiger Global and Sequoia India. The funds will be used to support CleverTap’s global expansion and enhance the development of its world-class solutions and technology. Founded in Mumbai in 2013 and headquartered in Mountain View, California, CleverTap’s customer engagement and retention SaaS platform leverages machine learning and artificial intelligence to offer a comprehensive user engagement suite that enables brands to build valuable, long-term relationships with their customers. CleverTap’s subscription-based solution has been adopted by a loyal customer base of 1,200 brands in 100 countries representing 10,000 apps across industries including Fintech, eCommerce, Subscription, On Demand, and Streaming media. In June 2022, CleverTap completed the acquisition of San Francisco-based Leanplum, a leading multi-channel customer engagement platform, further strengthening its footprint in North America and Europe. In the same month, it also unveiled TesseractDB™, the world’s first purpose-built database designed to dramatically improve user engagement and retention for digital consumer brands. “Our vision has been to reshape the way businesses engage with their consumers and bring the tech to MarTech. The addition of long-term investors CDPQ and IIFL AMC Tech fund to CleverTap’s existing backers, Sequoia India, Accel, Tiger Global, and Recruit Holdings is a great endorsement of the successful business we have built, the innovation we bring to the market and the growth potential CleverTap holds,” said Sunil Thomas, Co-founder and Executive Chairman, CleverTap. “The fresh funds will help fuel our plans to further strengthen our presence in key geographies and expand our teams. The last few months have been quite exciting for us with the Leanplum acquisition and unveiling of TesseractDB™. And now with the new institutional investors coming on board we have all that we need to grow at a faster rate while consolidating our position as the global leader in the retention space.” “CleverTap has established itself as a partner of choice for its clients by helping them generate significant incremental revenue. Its subscription-based platform offers a single and reliable source of information that allows brands to maximize the lifetime value of their existing customers by engaging them in a highly personalized way” said Martin Laguerre, Executive Vice-President and Head of Private Equity, CDPQ. “As consumer brands are increasingly focused on customer retention and prioritize tools offering tangible return on investment, we believe CleverTap is well positioned to maintain its global growth trajectory and help more businesses enhance their customer experience.” “CleverTap is a fast-growing SaaS company that not only has recurring revenue streams and top tier financial metrics, but also a scalable business model with large addressable markets” added Meng Ann Lim, Managing Director, Direct Private Equity for Asia Pacific, CDPQ. “This investment is in line with our strategy to work with innovative companies that enable rapid digital transformation, especially in the Asia-Pacific region where high smartphone penetration is facilitating the digitalization of the economy at a rapid pace.” “Enterprises are increasingly looking to engage with customers in a real time and in a personalized manner across digital channels. CleverTap’s full stack approach to customer engagement allows them to perform user analytics and run personalized customer campaigns on a real-time basis which enables companies to improve user retention and understand user journeys across channels” said Chetan Naik, Fund Manager and Senior Executive Vice-President, Private Equity at IIFL AMC. “CleverTap has built a unique product suite and analytics capabilities that runs over a proprietary database. CleverTap is one of the fastest growing SaaS companies with best-in-class revenue retention rates. We are excited to partner with them in their journey of creating a leading global customer retention platform out of India.” “The latest fundraise reaffirms customer and market belief in CleverTap and our growth potential. This fundraise will help us elevate our growth trajectory and further enable us to innovate better and faster while staying ahead of the curve,” said Sidharth Malik, Chief Executive Officer, CleverTap. “The paradigms of user engagement are changing, and as industry leaders we are best positioned to help businesses adapt to this ever-evolving consumer landscape. Our recent acquisitions helped us expand our foothold in North America and Europe, and enhance our leadership in verticals such as on-demand and subscription.” As part of the transaction, CDPQ will join CleverTap’s Board of Directors upon closure of this funding round. IIFL AMC’s investment is subject to approval from Securities and Exchange Board of India (SEBI). ABOUT CLEVERTAP CleverTap is the World’s No.1 retention cloud that empowers digital consumer brands to increase customer retention and lifetime value. CleverTap drives contextual individualization with the help of a unified and deep data layer, AI/ML-powered insights, and automation enabling brands to offer hyper-personalized and delightful experiences to their customers. 1,200 customers in 100 countries and 10,000 apps, including Gojek, ShopX, Canon, Electronic Arts, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa John’s, and Tesco, trust CleverTap to achieve their retention and engagement goals, growing their long-term revenue. Backed by leading investors such as Sequoia India, Tiger Global, Accel, CDPQ, IIFL and Recruit Holdings, the company is headquartered in Mountain View, California, with offices in Mumbai, Singapore, Sofia, São Paulo, Bogota, Amsterdam, Jakarta, and Dubai. For more information, visit clevertap.com or follow on LinkedIn and Twitter. ABOUT CDPQ At CDPQ, we invest constructively to generate sustainable returns over the long term. As a global investment group managing funds for public pension and insurance plans, we work alongside our partners to build enterprises that drive performance and progress. We are active in the major financial markets, private equity, infrastructure, real estate and private debt. As at December 31, 2021, CDPQ’s net assets totalled CAD 419.8 billion. For more information, visit cdpq.com, follow us on Twitter or consult our Facebook or LinkedIn pages. CDPQ is a registered trademark owned by Caisse de dépôt et placement du Québec and licensed for use by its subsidiaries. ABOUT IIFL AMC IIFL Asset Management (IIFL AMC) is a part of IIFL Wealth and Asset Management. IIFL AMC is an alternates-focused asset management and has been playing a pivotal role in the growth of the AIF industry in India. A disciplined and active management approach combined with research-led strategies allows IIFL AMC to tap into India’s potential for delivering on its commitments and long-term growth. The AMC’s diversified suite of mutual funds, PMS, alternative investment funds, credit funds and venture capital funds span public and private equities as well as fixed income securities and real estate. IIFL AMC’s distinctive products bring out the entrepreneurial edge, agility and speed of execution of a boutique asset management business, while providing gold standards of corporate governance of a large corporation with a long-term focus. Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or any related damages. Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

August 10, 2022 11:49 AM Eastern Daylight Time

Slashing Methane Emissions 30% By 2030 Could Be Key To Achieving Net Zero Targets — Here’s What AgTech Companies Are Doing To Help

Pond Technologies Holdings Inc.

The latest estimates put annual global methane emissions at 580 million tonnes (Mts) per year, creating atmospheric concentrations that are 2½ times denser than preindustrial levels. About 25% of that methane comes from the agricultural sector alone — mostly from gassy cows whose burps contain methane. With an estimated 1.4 billion cows worldwide and each cow belching approximately 220 pounds of methane each year, those burps add up. President Biden has even supported a bill that would tackle this issue, to the tune of $20 billion, due to its impact on the environment. That’s why companies like Pond Technologies Holdings Inc. ( OTCQB: PNDHF ) are exploring cost-effective, scalable ways to cut agricultural methane emissions and help nations around the world meet their Global Methane Pledge. Nations Need To Cut Methane Emissions If They Hope To Hit Net Zero Goals As part of the Global Methane Pledge launched at the 2021 United Nations Climate Change Conference (COP26) last year, 111 countries collectively responsible for 45% of methane emissions committed to reduce those emissions to 30% below 2020 levels by 2030. Methane is one of the most potent greenhouse gasses in Earth’s atmosphere — it has over 80 times the warming power of carbon dioxide and accounts for as much as 30% of the global temperature increase scientists expect to see in the next 20 years. Because of this enhanced warming effect, cutting 170 Mts, 30% of 2020 levels, in methane emissions would be the equivalent of scrubbing 4.7 billion to 6.1 billion tonnes of carbon dioxide emissions from the atmosphere per year. If the global temperature increase surpasses 1.5 C above its pre industrial average, scientists warn of the following changes in our climate could occur: Extreme heat events — like the recent record-breaking heat wave that swept Europe this summer, sparking wildfires in four countries and contributing to over 1,000 deaths — that used to happen once a decade or less would happen more than four times per decade. The risk of severe flooding will more than double for 73% of the world’s population. The total forest area at risk of forest fires would nearly double in the United States alone and fires could become about 37% more frequent. An average of more than 114 million people each month will be exposed to extreme drought conditions that could ruin food crops and make already-scarce drinking water even harder to come by. Curbing Agricultural Emissions Might Hinge On Discovering An Anti-Methane Diet For Livestock Methane in agriculture is produced primarily by livestock — especially cows — as their digestive process produces methane as a byproduct that is released when they burp. That means tackling methane levels for farmers means devising a way to make cows burp less. The approach that’s made the most progress is changing cows’ diet. Royal DSM (OTCQX: KDSKF), for example, has already shown some success with this approach using a feed additive called Bovaer that’s been shown to reduce methane from burping by around 30%. Algae May Hold Another Key To Slashing Methane Emissions In April, Pond Technologies partnered with Cross River Infrastructure Partners LLC and Livalta/AB Agri, a subsidiary of Associated British Foods plc (LSE: ABF) to identify algae strains that could reduce methane emissions when added to livestock feed. The research partnership could be a promising one as a separate study of red macroalgae (seaweed) found that it could cut methane emissions by up to 80% when added to cattle feed. However, scaling the production of seaweed would require turning large swaths of shorelines into seaweed farms, which could end up having its own environmental impacts on ocean and coastal ecosystems. That’s why Pond is partnering with these companies to explore microalgae strains that could offer the same methane-busting benefits as seaweed. Pond has already deployed what it reports is an innovative, scalable algae grow system that allows producers to grow microalgae in tanks where the conditions are optimized for algae growth. The tanks also help cut CO2 emissions themselves. Because algae use CO2 to grow, the proprietary Pond tanks can take the raw stack gas from power plants, factories and other high-emission facilities and convert it into clean, breathable air. The goal, then, is to identify microalgae strains that can be grown in these CO2-scrubbing platforms so that the companies can harvest them and turn them into feed additives. That way, each batch is pulling double duty: scrubbing emissions as it grows in the tank and curbing emissions again after it’s fed to livestock. Featured photo by Jan Koetsier on Pexels About Pond Technologies Located in Markham, Ontario, Pond has developed a proprietary system that can profitably transform CO2 into valuable products. Its Pond Carbon business focuses on absorbing greenhouse gas emissions, transforming these into food, feed, and nutraceutical ingredients. Pond recently added a Biotech division focused on the growth of unique strains of microalgae to be used as a reproductive medium for the expression of human antibodies and proteins. For more information, please visit https://www.pondtech.com/. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Pond Technologies, Inc. Grant Smith info@pondtech.com Benzinga Benzinga Brand Studio contributors@benzinga.com Company Website https://www.pondtech.com/

August 10, 2022 08:35 AM Eastern Daylight Time

Image

Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

NanoViricides, Inc.

https://profiles.smallcapsdaily.com/nnvc/ More than 30,000 confirmed or suspected cases of monkeypox have been reported across 93 countries in the world. While those numbers are still small scientists are now concerned that this sudden and unusual outbreak could lead to monkeypox becoming endemic in these large numbers of new countries where it was only seen sporadically before. With no specific treatment approved for the virus, doctors are turning to old smallpox medications — a disease that hasn’t had a reported case in nearly 50 years — and off-label use of an antiviral approved for smallpox that was developed as a medical countermeasure for potential bioterrorism, SIGA Technologies Inc. ’s (NASDAQ: SIGA) TPOXX. TPOXX has a number of shortcomings. Its injectable form requires each dosing to be infused over 6 hours, twice daily for several days. The injectable form may be considered rapid-acting, for severe cases, but cannot be given to patients with renal impairment (kidney damage). However, there is an oral capsule form. In terms of mechanism, TPOXX inhibits orderly exit of a mature virion. However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX. Most importantly, its utility in humans has not been established, as it was approved under the “Animal Rule” authority of the US FDA. It had shown effectiveness in monkeys to increase survival upon monkeypox virus infection. Importantly, TPOXX, during its development, has been known to give rise to resistant viruses or escape mutants. Something that scientists fear can give rise to new monkeypox viruses that may be worse than the current ones, as has been happening with the SARS-CoV-2 virus of COVID-19. Thus there is a clear and immediate need for rapid new drug development against monkeypox virus and potential variants. NanoViricides Inc. (NYSE American: NNVC ) reports that it may have a solution that would offer a more targeted treatment for the monkeypox virus that the virus may not escape from by mutations. The Strange And Sudden Outbreak Of Monkeypox What’s unusual about the outbreak is that although the “Patient Zero” in UK was connected to travel to Nigeria, and initial outbreaks occurred connected to raves in Europe, cases preceding to this outbreak have also been found to have occurred earlier, and not all the cases are linked to individuals who traveled to countries where the virus is usually found or have known contact with infected animals. While researchers are still trying to understand how that’s possible, the worry is that it’s been spreading silently and undetected for some time. And it can spread silently because an infected person is contagious even before the classic rash is present. The current outbreak also has different symptoms. Usually, a fever and swollen lymph nodes would precede the classic monkeypox rash and ulcers. However, with this virus, it appears that the rash can occur simultaneously with fever and swollen lymph nodes, or fever may even be absent. This is why possibly the rash of this virus was mistaken to be from other viruses such as herpes or shingles, although the monkeypox rashes behave distinctly differently from herpes or shingles rashes once formed. The Spread May Indicate Decreasing Immunity To Pox Viruses The monkeypox virus is a member of the poxviridae family along with smallpox, molluscum contagiosum and a few others. During the smallpox eradication program in the late 1960s, the vaccine used to prevent smallpox also helped curb monkeypox infections. Since 1980, smallpox has been declared to be entirely eradicated worldwide with successful worldwide vaccination campaigns. Smallpox does not have any animal reservoirs, it infects only humans, which contributed to its elimination. Monkeypox outbreaks have been regular in the endemic regions of Western and Central Africa, with annually thousands of cases. Many of these cases are deemed to be tied to transmission from animals rather than human to human transmission. But the recent uptick outside these regions may be related to the fact that many people born after the smallpox programs of the 60s stopped in 1980 have never had the smallpox vaccine. Even in those who received the smallpox vaccine, it has been over forty to sixty years, and the vaccine was expected to be effective for fifteen to twenty years only. With the last natural reported case of smallpox occurring in 1977, smallpox vaccines were seen as no longer necessary and widespread vaccination campaigns disappeared. While smallpox hasn’t come back, that decline in vaccination rates slowly brewed a generation of people who could be more vulnerable to other pox viruses in the family. The NanoViricides Platform May Offer A Rapidly Deployable Solution NanoViricides is a developmental-stage company working on an antiviral platform that a virus theoretically can’t outsmart. By chemically attaching a binding ligand to a nano-sized polymer, the company has created an antiviral that can attach to a virus’s binding site, which doesn’t mutate even as a virus evolves and looks similar across most viruses. Once attached, the nanoviricide engulfs the viral cell, blocking it from reproducing or infecting healthy cells. The company states that the broad-spectrum antiviral can be tailored to a wide range of viruses with the goal of providing a treatment that remains effective against just about any species and strain of virus that threatens the human population. With clinical candidates for COVID-19 and Shingles having successfully completed the full battery of IND-enabling studies, and preclinical research underway for a pipeline of additional treatments tailored to Herpesviruses, HIV, and more, the company has already found ways to adapt the platform to a broad range of difficult to treat viral infections. The company hopes to tailor an antiviral based on this platform to the recent and worrying resurgence of monkeypox cases. The Company has recently announced in its press releases that it is about to begin testing on its drug candidates for monkeypox virus treatment. The Company also said that it is following a two-pronged strategy: (a) The first one being to develop a quick drug to deploy rapidly that improves upon the existing drug tecovirimat so that it can be used widely including in patients that TPOXX is contraindicated; and (b) The second one being continued development of highly effective drugs against poxviruses and other DNA viruses that can add a strong drug to the current one-drug repertoire of poxvirus treatments. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com TraDigital IR Colette Eymontt colette@tradigitalir.com Company Website http://www.nanoviricides.com

August 10, 2022 08:00 AM Eastern Daylight Time

1 ... 215 216 217 218 219 ... 310